Concepts (242)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 20 | 2020 | 543 | 1.620 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 11 | 2017 | 236 | 0.940 |
Why?
|
| Thoracotomy | 4 | 2016 | 30 | 0.730 |
Why?
|
| Pneumonectomy | 5 | 2020 | 76 | 0.660 |
Why?
|
| Esophageal Neoplasms | 3 | 2015 | 50 | 0.570 |
Why?
|
| Thoracic Surgery, Video-Assisted | 3 | 2020 | 21 | 0.530 |
Why?
|
| Adenocarcinoma | 7 | 2015 | 135 | 0.520 |
Why?
|
| Unnecessary Procedures | 2 | 2019 | 26 | 0.500 |
Why?
|
| Biomarkers, Tumor | 5 | 2015 | 201 | 0.480 |
Why?
|
| Esophagectomy | 2 | 2011 | 23 | 0.450 |
Why?
|
| Barrett Esophagus | 4 | 2015 | 16 | 0.440 |
Why?
|
| Catheter Ablation | 4 | 2015 | 37 | 0.440 |
Why?
|
| Aged | 26 | 2019 | 7572 | 0.400 |
Why?
|
| Esophageal Diseases | 1 | 2011 | 4 | 0.360 |
Why?
|
| Jejunostomy | 1 | 2011 | 8 | 0.360 |
Why?
|
| Enteral Nutrition | 1 | 2011 | 61 | 0.350 |
Why?
|
| Male | 29 | 2019 | 12743 | 0.340 |
Why?
|
| Abnormalities, Drug-Induced | 4 | 2016 | 7 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2017 | 203 | 0.330 |
Why?
|
| Female | 30 | 2019 | 13239 | 0.320 |
Why?
|
| Neoplasm Staging | 12 | 2019 | 358 | 0.310 |
Why?
|
| Empyema, Pleural | 1 | 2009 | 1 | 0.310 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2009 | 4 | 0.310 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 61 | 0.300 |
Why?
|
| Postoperative Complications | 4 | 2016 | 837 | 0.290 |
Why?
|
| Surgical Wound Infection | 1 | 2009 | 79 | 0.290 |
Why?
|
| Positron-Emission Tomography | 3 | 2011 | 73 | 0.280 |
Why?
|
| Echinocandins | 3 | 2012 | 6 | 0.280 |
Why?
|
| Drainage | 2 | 2009 | 41 | 0.270 |
Why?
|
| Toxicity Tests | 4 | 2016 | 8 | 0.260 |
Why?
|
| Humans | 32 | 2020 | 23541 | 0.260 |
Why?
|
| Middle Aged | 20 | 2017 | 8134 | 0.260 |
Why?
|
| Retrospective Studies | 11 | 2017 | 3122 | 0.250 |
Why?
|
| Embryonic Development | 3 | 2016 | 7 | 0.250 |
Why?
|
| Embryo, Mammalian | 2 | 2016 | 24 | 0.220 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2019 | 164 | 0.220 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2015 | 14 | 0.220 |
Why?
|
| Aged, 80 and over | 12 | 2017 | 3767 | 0.210 |
Why?
|
| Bronchoscopy | 3 | 2019 | 33 | 0.200 |
Why?
|
| Pleurodesis | 1 | 2003 | 1 | 0.200 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2003 | 4 | 0.200 |
Why?
|
| Prognosis | 6 | 2017 | 749 | 0.200 |
Why?
|
| Consensus | 2 | 2020 | 85 | 0.200 |
Why?
|
| Treatment Outcome | 11 | 2017 | 3093 | 0.190 |
Why?
|
| Radiosurgery | 3 | 2011 | 32 | 0.180 |
Why?
|
| Antifungal Agents | 2 | 2012 | 39 | 0.180 |
Why?
|
| Survival Analysis | 5 | 2017 | 245 | 0.180 |
Why?
|
| Cohort Studies | 4 | 2017 | 1465 | 0.170 |
Why?
|
| Simulation Training | 1 | 2020 | 34 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 70 | 0.160 |
Why?
|
| Surgeons | 1 | 2020 | 79 | 0.160 |
Why?
|
| Computer Simulation | 1 | 2020 | 176 | 0.160 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 7 | 0.150 |
Why?
|
| False Positive Reactions | 1 | 2019 | 31 | 0.150 |
Why?
|
| Fetal Development | 2 | 2016 | 3 | 0.150 |
Why?
|
| Registries | 4 | 2015 | 179 | 0.150 |
Why?
|
| Fetus | 2 | 2016 | 33 | 0.150 |
Why?
|
| Risk Assessment | 4 | 2017 | 555 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 35 | 0.140 |
Why?
|
| Bone and Bones | 2 | 2016 | 109 | 0.140 |
Why?
|
| Length of Stay | 3 | 2016 | 305 | 0.140 |
Why?
|
| Clinical Competence | 2 | 2020 | 202 | 0.140 |
Why?
|
| Tracheomalacia | 1 | 2017 | 4 | 0.140 |
Why?
|
| Tracheal Stenosis | 1 | 2017 | 6 | 0.140 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 297 | 0.140 |
Why?
|
| Silicones | 1 | 2017 | 10 | 0.140 |
Why?
|
| Airway Obstruction | 1 | 2017 | 18 | 0.130 |
Why?
|
| Disease Progression | 4 | 2014 | 530 | 0.130 |
Why?
|
| Mutagenicity Tests | 1 | 2016 | 1 | 0.130 |
Why?
|
| Teratogens | 1 | 2016 | 1 | 0.130 |
Why?
|
| Hazardous Substances | 1 | 2016 | 2 | 0.130 |
Why?
|
| Pharmaceutical Preparations | 1 | 2016 | 7 | 0.130 |
Why?
|
| Stents | 1 | 2017 | 77 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 55 | 0.130 |
Why?
|
| Models, Animal | 1 | 2016 | 99 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 453 | 0.130 |
Why?
|
| Animals | 8 | 2016 | 3293 | 0.130 |
Why?
|
| Developmental Biology | 1 | 2016 | 1 | 0.130 |
Why?
|
| Ribs | 1 | 2016 | 12 | 0.130 |
Why?
|
| Thoracic Wall | 1 | 2016 | 12 | 0.120 |
Why?
|
| Metformin | 1 | 2016 | 15 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2016 | 35 | 0.120 |
Why?
|
| X-Ray Microtomography | 1 | 2016 | 72 | 0.120 |
Why?
|
| Rats | 5 | 2016 | 621 | 0.120 |
Why?
|
| Esophagoscopy | 1 | 2015 | 15 | 0.120 |
Why?
|
| Learning Curve | 1 | 2015 | 16 | 0.120 |
Why?
|
| Cytokines | 2 | 2014 | 206 | 0.120 |
Why?
|
| Thoracoscopy | 2 | 2019 | 22 | 0.120 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2014 | 10 | 0.110 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2014 | 10 | 0.110 |
Why?
|
| Prosthesis Failure | 1 | 2017 | 422 | 0.110 |
Why?
|
| Tumor Burden | 3 | 2010 | 24 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 148 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 168 | 0.100 |
Why?
|
| Intubation, Intratracheal | 2 | 2016 | 87 | 0.100 |
Why?
|
| Research Design | 2 | 2012 | 163 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2013 | 11 | 0.100 |
Why?
|
| Adult | 8 | 2017 | 7168 | 0.100 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2013 | 11 | 0.100 |
Why?
|
| Predictive Value of Tests | 4 | 2016 | 443 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 324 | 0.100 |
Why?
|
| Fundoplication | 1 | 2012 | 22 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 605 | 0.100 |
Why?
|
| Immunoassay | 1 | 2012 | 35 | 0.100 |
Why?
|
| Gastroesophageal Reflux | 1 | 2012 | 27 | 0.100 |
Why?
|
| Nitriles | 1 | 2012 | 13 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2016 | 322 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2012 | 23 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2017 | 172 | 0.090 |
Why?
|
| Triazoles | 1 | 2012 | 29 | 0.090 |
Why?
|
| Fistula | 1 | 2011 | 2 | 0.090 |
Why?
|
| Gastric Fistula | 1 | 2011 | 5 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2015 | 1532 | 0.090 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2011 | 7 | 0.090 |
Why?
|
| Nutrition Assessment | 1 | 2011 | 40 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2012 | 59 | 0.090 |
Why?
|
| Hospitals, Community | 1 | 2011 | 14 | 0.090 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 12 | 0.090 |
Why?
|
| Behavior, Animal | 1 | 2011 | 46 | 0.090 |
Why?
|
| Algorithms | 3 | 2014 | 317 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 15 | 0.090 |
Why?
|
| Risk Factors | 5 | 2015 | 1997 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2011 | 59 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2011 | 44 | 0.090 |
Why?
|
| Minority Groups | 1 | 2011 | 66 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2010 | 18 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2010 | 21 | 0.080 |
Why?
|
| Age Factors | 2 | 2009 | 648 | 0.080 |
Why?
|
| Bronchi | 1 | 2010 | 12 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 196 | 0.080 |
Why?
|
| Patient Selection | 1 | 2011 | 170 | 0.080 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2009 | 9 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 167 | 0.080 |
Why?
|
| Trachea | 1 | 2010 | 39 | 0.080 |
Why?
|
| Probability | 1 | 2009 | 73 | 0.080 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 105 | 0.080 |
Why?
|
| Thoracic Surgery | 1 | 2009 | 26 | 0.080 |
Why?
|
| Body Mass Index | 1 | 2011 | 403 | 0.080 |
Why?
|
| Area Under Curve | 3 | 2014 | 59 | 0.080 |
Why?
|
| Survival Rate | 2 | 2010 | 323 | 0.080 |
Why?
|
| United States | 4 | 2015 | 1837 | 0.070 |
Why?
|
| Staphylococcus aureus | 1 | 2009 | 70 | 0.070 |
Why?
|
| Recurrence | 2 | 2014 | 276 | 0.070 |
Why?
|
| Neoplasms | 1 | 2011 | 223 | 0.070 |
Why?
|
| Rats, Inbred F344 | 3 | 2012 | 33 | 0.070 |
Why?
|
| Laparoscopy | 1 | 2009 | 185 | 0.070 |
Why?
|
| Staphylococcal Infections | 1 | 2009 | 157 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 90 | 0.060 |
Why?
|
| Time Factors | 3 | 2015 | 1293 | 0.060 |
Why?
|
| Rabbits | 2 | 2016 | 165 | 0.060 |
Why?
|
| Lung | 2 | 2005 | 153 | 0.060 |
Why?
|
| Pregnancy | 3 | 2012 | 322 | 0.060 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2009 | 293 | 0.060 |
Why?
|
| Pneumonia | 2 | 2019 | 69 | 0.060 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2005 | 2 | 0.060 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 2005 | 6 | 0.060 |
Why?
|
| Logistic Models | 2 | 2015 | 357 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2014 | 1492 | 0.050 |
Why?
|
| Brain | 1 | 2011 | 1215 | 0.050 |
Why?
|
| ROC Curve | 2 | 2014 | 127 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 603 | 0.050 |
Why?
|
| Catheters, Indwelling | 1 | 2003 | 21 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 644 | 0.050 |
Why?
|
| Proton Pump Inhibitors | 2 | 2012 | 11 | 0.050 |
Why?
|
| Reoperation | 2 | 2015 | 767 | 0.040 |
Why?
|
| Sex Factors | 2 | 2012 | 393 | 0.040 |
Why?
|
| Mediastinoscopy | 1 | 2019 | 6 | 0.040 |
Why?
|
| Radiography | 2 | 2013 | 555 | 0.040 |
Why?
|
| Young Adult | 2 | 2014 | 1745 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 101 | 0.040 |
Why?
|
| Dilatation | 1 | 2017 | 10 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 15 | 0.030 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2016 | 8 | 0.030 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 13 | 0.030 |
Why?
|
| Tracheostomy | 1 | 2016 | 21 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 88 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 316 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 56 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 15 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 20 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hospitals, Low-Volume | 1 | 2015 | 5 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2015 | 7 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 276 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 126 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 58 | 0.030 |
Why?
|
| Remission Induction | 1 | 2015 | 89 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 110 | 0.030 |
Why?
|
| Biomarkers | 1 | 2017 | 482 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 229 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 194 | 0.030 |
Why?
|
| Minnesota | 1 | 2014 | 6 | 0.030 |
Why?
|
| Illinois | 1 | 2014 | 222 | 0.030 |
Why?
|
| Chemokine CCL3 | 1 | 2013 | 8 | 0.030 |
Why?
|
| Granuloma | 1 | 2013 | 13 | 0.030 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2013 | 13 | 0.030 |
Why?
|
| Chemokine CXCL12 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2013 | 18 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2013 | 24 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2013 | 70 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 40 | 0.020 |
Why?
|
| Maternal Exposure | 1 | 2012 | 1 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2012 | 87 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 21 | 0.020 |
Why?
|
| Voriconazole | 1 | 2012 | 10 | 0.020 |
Why?
|
| Drug Combinations | 1 | 2012 | 32 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2012 | 32 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 29 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2012 | 41 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2012 | 29 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 170 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2012 | 99 | 0.020 |
Why?
|
| Body Weight | 1 | 2012 | 129 | 0.020 |
Why?
|
| Hematemesis | 1 | 2011 | 2 | 0.020 |
Why?
|
| Stomach Ulcer | 1 | 2011 | 4 | 0.020 |
Why?
|
| Esophageal Perforation | 1 | 2011 | 8 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2011 | 20 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 51 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2012 | 79 | 0.020 |
Why?
|
| Osteogenesis | 1 | 2012 | 101 | 0.020 |
Why?
|
| Candidiasis | 1 | 2011 | 23 | 0.020 |
Why?
|
| Michigan | 1 | 2011 | 17 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 65 | 0.020 |
Why?
|
| Contrast Media | 1 | 2011 | 60 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2011 | 48 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2010 | 6 | 0.020 |
Why?
|
| Organogenesis | 1 | 2010 | 2 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 114 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2010 | 25 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2010 | 15 | 0.020 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 75 | 0.020 |
Why?
|
| Hospitalization | 1 | 2012 | 292 | 0.020 |
Why?
|
| Rupture | 1 | 2010 | 85 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 431 | 0.020 |
Why?
|
| Motor Activity | 1 | 2011 | 275 | 0.020 |
Why?
|
| Mice | 1 | 2012 | 1244 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2007 | 94 | 0.020 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2007 | 48 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 134 | 0.010 |
Why?
|
| Cognition | 1 | 2011 | 948 | 0.010 |
Why?
|
| Aging | 1 | 2012 | 1101 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 285 | 0.010 |
Why?
|